טוען...
Molecular targeted therapy of BRAF-mutant colorectal cancer
Over the past two decades, the molecular characterization of metastatic colorectal cancer (mCRC) has been revolutionized by the routine implementation of RAS and BRAF tests. As a result, it is now known that patients with mCRC harboring BRAF mutations experience a poor prognosis. Although it account...
שמור ב:
| הוצא לאור ב: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6582307/ https://ncbi.nlm.nih.gov/pubmed/31244912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919856494 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|